Opportunity
Movement disorders, often resulting from brain injuries such as stroke, are a leading cause of adult disability worldwide. Stroke, in particular, is a major contributor to mortality and long-term impairment, with its prevalence rising due to aging populations. Existing rehabilitation methods primarily rely on motor training, which is often prolonged and inefficient for restoring movement ability. While pharmacological approaches targeting neuronal plasticity have been explored alongside training, current drugs suffer from limited efficacy across diverse patient populations and significant side effects. There is a critical, unmet need for novel, effective, and well-tolerated therapies to enhance motor recovery and learning in patients with movement disorders.
Technology
This patent discloses a novel therapeutic method centered on administering a CCK-B receptor agonist, such as the tetrapeptide CCK4, to treat movement disorders and regain motor learning ability. The innovation is based on the discovery that cholecystokinin (CCK) signaling is essential for neuronal plasticity within the motor cortex, which is the brain center for controlling skilled movements. The invention demonstrates that genetic knockout of CCK or pharmacological blockade of CCK-B receptors in the motor cortex impairs motor skill learning and long-term potentiation (LTP), a cellular correlate of memory and plasticity. Conversely, administration of a CCK-B receptor agonist, particularly CCK4, rescues these deficits. The technology involves targeted activation of CCK-B receptors to "turn on" neuronal plasticity, thereby enabling the brain, especially in adults where plasticity is limited, to relearn and regain motor functions. Key aspects include the use of CCK4, which can cross the blood-brain barrier, and administration via routes such as intraperitoneal or intravenous injection at low doses (e.g., about 0.0036 mg/kg to 0.036 mg/kg) over a period such as one to four weeks.
Advantages
- Provides a novel pharmacological target (CCK-B receptor) for treating movement disorders.
- CCK4, a key agonist, can effectively cross the blood-brain barrier.
- Demonstrates high efficacy in rescuing motor learning ability in preclinical models.
- Operates at low dosages, potentially minimizing side effects.
- Specifically enables neuronal plasticity in the adult motor cortex, addressing a key limitation in recovery.
- Offers a complementary approach that can be combined with existing rehabilitation training.
- Targets the root cause of motor learning deficits by modulating synaptic plasticity.
Applications
- Treatment of movement disorders resulting from stroke (ischemic, hemorrhagic).
- Rehabilitation following brain injury or physical trauma to the motor cortex.
- Therapy for conditions such as Parkinson's disease, Chorea, and Dystonia.
- Addressing motor deficits associated with brain infarction or neuron loss due to aging.
- Use in pharmaceutical compositions for intraperitoneal, intravenous, or intramuscular administration.
- Application in regimens for regaining motor learning ability in adult patients.
